GLP-1 receptor agonists produce weight loss by reducing appetite and caloric intake. The drugs have no mechanism that selectively removes fat while preserving muscle. In the absence of specific countermeasures, a substantial proportion of the weight lost will be lean mass. The clinical evidence is clear on this and equally clear on the solution: progressive resistance training combined with high protein intake meaningfully attenuates lean mass loss during caloric restriction, including the caloric restriction produced by GLP-1 medication.
The Role of Resistance Training
Resistance training provides the anabolic stimulus that signals to the body to preserve skeletal muscle during a caloric deficit. Without this signal, the body has no metabolic reason to maintain expensive muscle tissue when overall energy availability is reduced. A 2022 meta-analysis in the British Journal of Sports Medicine, examining 58 studies of resistance training during caloric restriction, found that resistance training preserved approximately 1.5 kilograms of additional lean mass compared to caloric restriction alone, with the effect increasing with training frequency and volume.
For GLP-1 users specifically, the STEP-HFpEF trial of semaglutide found that participants who engaged in structured exercise alongside medication preserved significantly more lean mass than those receiving medication alone. The protocol used in that trial included resistance training three times weekly. This frequency appears to be the minimum threshold for meaningful lean mass preservation in the context of pharmacologically induced caloric restriction.
Protein Intake: Why the Requirement Increases on GLP-1 Drugs
GLP-1 medications reduce appetite without distinction: patients typically eat less of everything, including protein. If total protein intake falls proportionally with total caloric intake, the already-insufficient protein available for muscle protein synthesis becomes further depleted. Research from the Maastricht University Medical Centre found that adults in caloric restriction require a minimum of 1.6 grams of protein per kilogram of body weight daily to maintain lean mass. For the appetite suppression levels typically produced by GLP-1 drugs, achieving this target requires deliberate prioritisation of protein at every meal.
The practical approach is to structure meals around protein sources first. When appetite is suppressed, volume tolerance is limited. Filling available stomach volume with protein before other foods ensures that the nutrient most critical to muscle preservation is consumed before appetite is exhausted. High-density protein sources including eggs, Greek yoghurt, cottage cheese, chicken breast, fish, and lean meat provide large amounts of protein in modest volumes and are well tolerated even at reduced appetite.
Practical Protocol for GLP-1 Users
Begin resistance training before starting GLP-1 treatment where possible. Establishing the training habit and initial adaptations before appetite suppression begins makes it significantly easier to sustain during the early weeks of medication when GI side effects are most pronounced. During treatment, three resistance training sessions per week targeting all major muscle groups, with progressive loading over time, represents the evidence-based minimum. Sessions of 30 to 45 minutes are sufficient when structured around compound movements including squats, deadlifts, rows, and pressing patterns.
- Resistance training three times per week targeting all major muscle groups is the evidence-based minimum
- Compound movements: squats, deadlifts, rows, pressing and hinging patterns
- Protein target: 1.6 to 2.2 grams per kilogram of body weight daily throughout treatment
- Prioritise protein first at each meal when total appetite is suppressed
- High-density protein sources: eggs, Greek yoghurt, cottage cheese, chicken, fish, lean meat
- Begin resistance training before GLP-1 treatment starts where clinically feasible
- Track lean mass with DEXA or bioelectrical impedance at treatment start, mid-point, and end